82717-30-4 Usage
Uses
Used in Pharmaceutical Industry:
Decahydro-3-isoquinolinecarboxylic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential as an anti-inflammatory and anti-cancer agent. Its unique chemical structure allows for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
Decahydro-3-isoquinolinecarboxylic acid is used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals with enhanced efficacy and selectivity.
Used in Research and Development:
Decahydro-3-isoquinolinecarboxylic acid is used as a building block for the synthesis of various functional materials in research and development. Its versatile chemical properties enable the creation of new compounds with potential applications in various industries, including materials science, nanotechnology, and biotechnology.
Used in Drug Discovery:
Decahydro-3-isoquinolinecarboxylic acid is used as a starting material in drug discovery for its potential to form biologically active molecules. Its unique structure and properties make it a valuable component in the development of new therapeutic agents with novel mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 82717-30-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,7,1 and 7 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 82717-30:
(7*8)+(6*2)+(5*7)+(4*1)+(3*7)+(2*3)+(1*0)=134
134 % 10 = 4
So 82717-30-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H17NO2/c12-10(13)9-5-7-3-1-2-4-8(7)6-11-9/h7-9,11H,1-6H2,(H,12,13)
82717-30-4Relevant academic research and scientific papers
Modified position (7) bradykinin antagonist peptides
-
, (2008/06/13)
The substitution of the L-Pro at the 7-position of the peptide hormone bradykinin or other substituted analogs of bradykinin with an isoquinoline derivative which converts bradykinin agonists into bradykinin antagonists. The invention further includes the novel 7-position modified bradykinin antagonists which increase enzyme resistance, antagonist potency, and/or specificity of the new bradykinin antagonists. The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected as by insect bites.
